论文部分内容阅读
慢性心力衰竭的病理生理基础是多种内源性神经内分泌和细胞因子的激活,而导致心衰发生发展的基本机制是左室重构,因此,目前临床上治疗心衰的关键是阻断神经内分泌系统过度激活及阻断心肌重构,而有关研究证实[1],替米沙坦做为一种新型血管紧张素Ⅱ受体拮抗剂能够明显延缓心力衰?
The pathophysiology of chronic heart failure is a variety of endogenous neuroendocrine and cytokine activation, and lead to the development of heart failure is the basic mechanism of left ventricular remodeling, therefore, the current clinical treatment of heart failure is the key to blocking the nerve Endocrine system over-activation and block myocardial remodeling, and the study confirmed [1], telmisartan as a new type of angiotensin Ⅱ receptor antagonist can significantly delay heart failure?